Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
To experience MinuteCE for yourself, select one of the episodes below to start learning!
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage II Melanoma
What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage II Melanoma
Future Directions: Targeting LAG-3 in Melanoma Treatment
Future Directions: Targeting LAG-3 in Melanoma Treatment
Optimizing Resectable Melanoma Outcomes Through Multidisciplinary Care and Multimodal Treatment Strategies
Optimizing Resectable Melanoma Outcomes Through Multidisciplinary Care and Multimodal Treatment Strategies
What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage III/IV Melanoma
What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage III/IV Melanoma
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
ATTRv-PN: A Complicated Disease With a Poor Prognosis
ATTRv-PN: A Complicated Disease With a Poor Prognosis
Advancing the Treatment of ATTRv-PN: What's in the Pipeline?
Advancing the Treatment of ATTRv-PN: What's in the Pipeline?
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
